Panaxatriol exerts anti-senescence effects and alleviates osteoarthritis and cartilage repair fibrosis by targeting UFL1

• Published in: Journal of advanced research 2024-10
• Main Authors: Kuang, Biao, Geng, Nana, Yi, Miao, Zeng, Qiqi, Fan, Mengtian, Xian, Menglin, Deng, Lin, Chen, Cheng, Pan, Yiming, Kuang, Liang, Luo, Fengtao, Xie, Yangli, Liu, Chao, Deng, Zhongliang, Nie, Mao, Du, Yu, Guo, Fengjin
• Format: Article
• Language: English
• Subjects: Cell senescence; Fibrosis; Osteoarthritis; Panaxatriol; PLGA; UFL1
• ISSN: 2090-1232; 2090-1224; 2090-1224
• DOI: 10.1016/j.jare.2024.10.016

[Display omitted] •Panaxatriol can delay the progression of OA and relieve pain in a surgically induced mouse model of OA.•Ubiquitin-fold modifier 1-specific E3 ligase 1 (UFL1) was isolated as a novel panaxatriol target.•Panaxatriol can alleviate cellular senescence through UFL1/FOXO1/P21 and UFL1/NF-κB/SASPs signaling pathways.•Panaxatriol also reduced cartilage repair fibrosis through the UFL1/FOXO1/COL1 signaling pathway. Osteoarthritis (OA), the most common degenerative joint disease, can eventually lead to disability. However, no safe or effective intervention is currently available. Therefore, there is an urgent need to develop effective drugs that reduce cartilage damage and treat OA. This study aimed to ascertain the potential of panaxatriol, a natural small molecule, as a therapeutic drug for alleviating the progression of OA. An in vitro culture of human cartilage explants and C28/I2 human chondrocytes and an in vivo surgically induced OA mouse model were used to evaluate the chondroprotective effect of panaxatriol. The Drug Affinity Responsive Target Stability assay, CRISPR-Cas9 assay, Whole-transcriptome RNA sequencing analysis and agonist or antagonist assays were used to identify the target and potential signaling pathways of panaxatriol. Poly(lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG) was used to construct the sustained-release system of panaxatriol. Panaxatriol protected against OA by regulating chondrocyte metabolism. Ubiquitin-fold modifier 1-specific E3 ligase 1 (UFL1) was identified as a novel target of panaxatriol. Whole transcriptome RNA sequencing showed that UFL1 was closely related to cell senescence. Panaxatriol inhibited chondrocyte senescence through UFL1/forkhead box O1 (FOXO1)/P21 and UFL1/NF-κB/SASPs signaling pathways. It also could inhibit fibrocartilage formation during cartilage repair via the UFL1/FOXO1/Collagen 1 signaling pathway. Finally, we constructed a sustained-release system for panaxatriol based on PLGA-PEG, which reduced the number of intra-articular injections, thereby alleviating joint swelling and injury. Panaxatriol exerts anti-senescence effects and has the potential to delay OA progression and reduce cartilage repair fibrosis by targeting UFL1.